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Oxidized LDL induces changes in several facets of the immune system, although the relationships between these facets
and their contributions to atherogenesis have yet to be fully elucidated. A report in this issue of the JCI provides a novel
demonstration of the adaptive immune system influencing the production of natural antibodies. The results demonstrate
that injection of malondialdehyde-modified LDL promotes a Th2 response that in turn increases the titers of the natural
antibody T15/EO6, which recognizes the oxidized phospholipid POVPC. Atherosclerotic lesion size in LDL receptor–
deficient mice is reduced as a consequence of the increase in natural antibody titers, and IL-5 is identified as the link
between the adaptive and natural immune systems.
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IL-5 links adaptive and natural immunity  
in reducing atherosclerotic disease
Alan Daugherty, Debra L. Rateri, and Victoria L. King
Gill Heart Institute, University of Kentucky, Lexington, Kentucky, USA.
Oxidized LDL induces changes in several facets of the immune system, 
although the relationships between these facets and their contributions to 
atherogenesis have yet to be fully elucidated. A report in this issue of the JCI 
provides a novel demonstration of the adaptive immune system influencing 
the production of natural antibodies. The results demonstrate that injection 
of malondialdehyde-modified LDL promotes a Th2 response that in turn 
increases the titers of the natural antibody T15/EO6, which recognizes the 
oxidized phospholipid POVPC. Atherosclerotic lesion size in LDL recep-
tor–deficient mice is reduced as a consequence of the increase in natural anti-
body titers, and IL-5 is identified as the link between the adaptive and natural 
immune systems (see related article beginning on page 427).
Several decades ago it was proposed that oxi-
dative modification of LDL promoted the 
formation of atherosclerotic lesions (1). Early 
studies focused on the ability of oxidized 
LDL (OxLDL) to bind macrophage scaven-
ger receptors as a mechanism for the forma-
tion of lipid-laden foam cells that are present 
throughout the evolution of atherosclerotic 
lesions. Subsequent studies have demon-
strated that oxidatively modified LDL is a 
complex entity with a range of atherogenic 
properties that affect macrophages. These 
include promotion of macrophage recruit-
ment and retention, lipid loading via mul-
tiple receptor types, induction of inflamma-
tory genes, and cell viability (2).
Although the role of macrophages ini-
tially took center stage in atherosclerosis 
research, there is a growing literature on 
the interaction of OxLDL with both the 
cell-mediated and humoral components 
of the adaptive immune system. Cell-medi-
ated responses were demonstrated follow-
ing OxLDL stimulation of T lymphocyte 
clones isolated from atherosclerotic lesions 
(3). In addition, many studies have dem-
onstrated humoral immune responses in 
reaction to the presence of autoantibodies 
to specific forms of OxLDL, particularly 
malondialdehyde-modified LDL (MDA-
LDL) (4). Although autoantibodies to 
OxLDL are consistently found in hyperlip-
idemic animals and humans, their impact 
on the atherosclerotic process is unclear. 
Higher titers of these autoantibodies often 
positively correlate with severity of athero-
sclerosis, which led to conjecture regard-
ing their involvement in the disease pro-
cess. For example, titers of autoantibodies 
to selected forms of OxLDL have been 
shown to predict the severity of human 
carotid atherosclerosis (5). To determine 
whether these correlations were causal, 
autoantibody titers were increased by 
immunizing hyperlipidemic rabbits and 
mice with different forms of modified LDL, 
which produced an unanticipated result: 
immunization with MDA-LDL actually 
decreased the size of atherosclerotic lesions 
in Watanabe heritable hyperlipidemic rab-
bits (6). Subsequent studies in rabbits and 
mice have shown some anomalies in the 
antibody isotypes developed during immu-
nization but have consistently demonstrat-
ed a decrease in atherosclerotic lesion size 
in response to immunization with different 
forms of OxLDL (7, 8).
OxLDL autoantibodies  
in apoE–/– mice
apoE–/– mice represent a widely used ani-
mal model of atherosclerosis, and they 
develop autoantibody titers to modified 
LDL independent of immunization (9). 
Witztum and colleagues previously capi-
talized on this observation by creating a 
panel of monoclonal antibodies from the 
spleens of aged apoE–/– mice. This panel 
has proven to be invaluable for the iden-
tification of oxidative products formed 
in these hyperlipidemic mice (10). All of 
the characterized monoclonal antibodies 
are IgMs. The most extensively charac-
terized IgM anti-OxLDL antibody, EO6, 
reacts against an oxidized phospholipid in 
modified LDL that has been identified as 
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-
phosphorylcholine (POVPC). EO6 exerts 
functional effects by binding selectively to 
oxidized LDL and blocking macrophage 
lipid accumulation (11). An interesting 
extension of this story is the finding that 
EO6 is indistinguishable from the natural 
antibody T15, which is secreted by a spe-
cialized subclass of B lymphocytes termed 
B-1 cells (12). Hence, this antibody is now 
commonly referred to as T15/EO6. The 
function of natural antibodies has not 
been defined, but they are thought to rep-
resent part of an innate system that affords 
protection from microorganisms. For 
example, the T15 antibody confers protec-
tion from Streptococcus pneumoniae infec-
tion in mice. Binder et al. have previously 
demonstrated a link between the T15 anti-
body and atherosclerosis by increasing T15 
antibody titers by S. pneumoniae immuniza-
tion and observing a concomitant reduc-
tion in atherosclerotic lesion size in LDL 
receptor–deficient mice (13).
How does adaptive immunity  
affect natural antibodies?
In this issue of the JCI, Binder et al. have 
elucidated a mechanism of the paradox of 
immunization with MDA-LDL producing 
a T lymphocyte–dependent increase in the 
titers of T15/EO6 antibodies and a reduc-
tion in the size of atherosclerotic lesions in 
LDL receptor–deficient mice. Thus, activa-
tion of the adaptive immune system led to 
a protective effect that was attributed to 
augmentation of natural immunity. Fur-
thermore, they identify IL-5 as the critical 
link between these two distinct forms of 
immune responses (Figure 1) (14).
Binder et al. demonstrate that immuniza-
tion of wild-type C57BL/6 mice with MDA-
Nonstandard abbreviations used: malondialdehyde-
modified LDL (MDA-LDL); oxidized LDL (OxLDL); 
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphoryl-
choline (POVPC).
Conflict of interest: The authors have declared that no 
conflict of interest exists.
Citation for this article: J. Clin. Invest. 114:317–319 
(2004). doi:10.1172/JCI200422561.
commentaries
318 The Journal of Clinical Investigation   http://www.jci.org   Volume 114   Number 3   August 2004
LDL led to a predominantly Th2 immune 
response (14). Antigen challenge resulted 
in the induction of MDA-LDL–specific 
IgG1 isotype autoantibodies and the 
release of IL-5 and IL-13 from splenocytes. 
Immunization of hypercholesterolemic, 
LDL receptor–deficient mice also led to 
enhanced IgG1 autoantibody titers. This 
production of IgG1 isotype autoantibodies 
against MDA-LDL was noted previously 
during severe hypercholesterolemia (15). 
Immunization also led to a decrease in 
atherosclerotic lesion size that was selec-
tive for the aortic root. Splenocytes from 
these mice preferentially secreted selected 
Th2 cytokines, including IL-5, IL-10, and 
IL-13, when exposed to MDA-LDL. These 
cytokines were secreted in equivalent mass 
from splenocytes when antigen challenged 
in the absence of costimulation with CD28. 
However, in the presence of CD28 stimu-
lation, IL-5 was the most highly secreted 
cytokine from splenocytes in response to 
MDA-LDL challenge. In addition, MDA-
LDL immunization also produced an 
increase in plasma concentrations of IL-5. 
Other Th2 cytokines were not measured.
This increased adaptive immune response 
to MDA-LDL was associated with elevated 
titers of the T15/EO6 natural antibody. This 
was unexpected since the POVPC epitope 
recognized by T15/EO6 was not present in 
the immunizing material (14). Basing their 
ideas in part on the preferential secretion of 
IL-5 promoted by MDA-LDL immunization, 
the authors speculated that the release of 
this cytokine augmented the production of 
natural antibodies. This notion was support-
ed by several observations including: (a) IL-5 
promoted T15/EO6 secretion from cultured 
B-1 cells; (b) intraperitoneal injections of 
IL-5 into naive C57BL/6 mice increased T15/
EO6 titers; and (c) IL-5–deficient mice had 
reduced T15/EO6 titers. Furthermore, the 
IL-5 genotype had no effect on the titers of 
IgG1 and IgG2a raised following immuniza-
tion with MDA-LDL, while an IL-5 deficien-
cy ablated the increased IgM titers elicited in 
response to MDA-LDL immunization.
IL-5 regulates atherosclerotic  
lesion size
The final step in this study was to define 
the effect of IL-5 deficiency on the develop-
ment of atherosclerosis. This was achieved 
by irradiating LDL receptor–deficient mice 
and reconstituting them with bone mar-
row–derived stem cells from either IL-5 
wild-type or deficient mice (14). After an 
engraftment period, mice were fed a high-
fat diet. The group reconstituted with bone 
marrow–derived stem cells harvested from 
IL-5 wild-type mice had decreased athero-
sclerotic lesion size. This decrease in lesion 
size in mice secreting IL-5 occurred in 
both the aortic root and the aortic intima 
in contrast to the site-selective effects of 
MDA-LDL immunization.
These studies establish a working para-
digm for further research. This will include 
determining whether MDA-LDL immuni-
zation has any effect on the development 
of atherosclerosis in IL-5–deficient mice. It 
will also be important to establish whether 
IL-5 is the exclusive cytokine that links the 
effects of adaptive and natural immunity 
in atherogenesis. Other Th2 cytokines, par-
ticularly IL-10, have established antiathero-
genic properties, although links to humoral 
responses have not been elucidated (16–18). 
Furthermore, the studies of Binder et al. 
Figure 1
The sequence of events elucidated by Binder 
et al. (14) define the link between adaptive 
and natural immunity in atherogenesis. MDA-
LDL immunization of LDL receptor–deficient 
mice led to a Th2 immune response. This was 
demonstrated by the predominance of IgG1 
isotype antibodies against MDA-LDL that were 
generated during immunization. Also, antigen 
challenge of splenocytes led to secretion of 
the Th2 cytokines: IL-5, IL-10, and IL-13. 
IL-5 secretion promoted an increase in titers 
of natural antibodies, termed T15/EO6. These 
antibodies recognize an oxidized phospholip-
id, POVPC, that is not present in the immuniz-
ing material. The T15/EO6 antibody has been 
previously shown to inhibit OxLDL recognition 
by macrophages, which may account for the 
reduction in atherosclerotic lesion size.
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(14) have demonstrated that the effects of 
MDA-LDL immunization are associated 
with increased titers of the IgM-antibody 
isotype. However, future studies will need to 
determine the relative contribution of T15/
EO6 IgMs to the reduction in atherosclero-
sis versus that of other IgMs that are formed 
during MDA-LDL immunization. Finally, it 
will be important to determine whether the 
T15/EO6-mediated inhibition of OxLDL 
uptake by macrophages observed in cul-
tured cells is the mechanism responsible for 
the reduced atherosclerotic lesion size.
Overall, these studies have mapped out an 
interesting and novel pathway linking the 
adaptive and natural arms of the immune 
system (14). These findings also highlight a 
practical issue that needs to be considered 
for future therapeutic strategies. Specifical-
ly, antagonists of IL-5 are being developed 
for asthma therapy. The studies of Binder 
et al. indicate that it will be important to 
determine the ramifications of such a ther-
apy on vascular disease.
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Pulmonary fibrosis: thinking outside of the lung
Stavros Garantziotis,1 Mark P. Steele,1 and David A. Schwartz1,2
1Department of Medicine at Duke University Medical Center; 2Durham Department of Veterans Affairs Medical Center, Durham, North Carolina, USA.
Pulmonary fibrosis is a devastating condition that leads to progressive lung 
destruction and scarring. Previous mechanistic research has focused on the 
local fibroproliferative process in the lung. However, emerging evidence sug-
gests that circulating cells of hematopoietic origin play a crucial role in the 
pathogenesis of this disease (see the related article beginning on page 438).
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(IIP); idiopathic pulmonary fibrosis (IPF).
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Idiopathic interstitial pneumonias (IIPs; 
see Table 1) are a group of devastating con-
ditions isolated to the lung and, except by 
lung transplantation, often are untreat-
able. While idiopathic pulmonary fibrosis 
(IPF) is the most common type of IIP and 
involves dense fibrosis with active areas of 
fibroproliferation, other forms of IIP are 
characterized by varying degrees of inflam-
mation in addition to the active fibropro-
liferative process. Although pulmonary 
fibrosis has traditionally been thought to 
develop in response to chronic inflamma-
tion in the lung parenchyma, emerging 
evidence suggests that repeated exogenous 
and endogenous stimuli cause sequen-
tial lung injury that results in pulmonary 
fibrosis in individuals unable to effectively 
heal the damage (Figure 1) (1).
The key to understanding the complex 
pathogenesis of IIP may lie in the answers 
to two very simple questions: why is this 
condition isolated to the lung, and do fac-
tors outside of the lung affect the patho-
genesis of this disease?
Circulating fibrocytes and  
pulmonary fibrosis
In this issue of the JCI, Phillips and col-
leagues (2) endeavor to answer these ques-
tions by identifying the circulating fibro-
cyte and chemokine gradients critical to 
the fibroproliferative process in a murine 
model of bleomycin-induced pulmonary 
fibrosis. Fibrocytes are a unique popula-
tion of circulating cells of hematopoietic 
origin that produce ECM proteins (e.g., 
fibroblast-like collagen and vimentin and 
myofibroblast-like α-smooth muscle actin) 
and differentiate into myofibroblasts (3). 
These cells are characterized by specific 
